Form 4: CorMedix COO Granted 93,010 Restricted Stock Units

CorMedix Inc.'s Chief Operating Officer, Elizabeth Hurlburt, was granted 93,010 restricted stock units, with a portion immediately vesting and the remainder vesting over three years.

Summary

• Elizabeth Hurlburt, Chief Operating Officer of CorMedix Inc. [CRMD], reported transactions on January 23, 2026.
• She was granted 93,010 restricted stock units (RSUs) at a price of $0.00 per unit.
• Each RSU represents the right to receive one share of CorMedix Inc. common stock.
• The RSUs vest 1/4 on the grant date, and 1/4 on each of the first, second, and third anniversaries of the grant date, contingent on continued employment.
• Concurrently, 10,778 shares of common stock were disposed of at $7.27 per share, likely for tax withholding purposes related to the RSU grant/vesting.
• Following these transactions, Elizabeth Hurlburt beneficially owns 242,533 shares of common stock directly.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a key executive is a positive for aligning management incentives with shareholder value and retention. The disposition for tax purposes is routine. Overall, it's a standard, slightly positive corporate governance event.

Positives

• Grant of 93,010 restricted stock units to the Chief Operating Officer aligns management's interests with long-term shareholder value.
• The vesting schedule over three years encourages retention of key executive talent.

Negatives

• Disposition of 10,778 shares, while likely for tax purposes, represents a reduction in direct shareholding.

Future Outlook

The vesting schedule for the restricted stock units extends over three years, indicating a long-term incentive for the Chief Operating Officer to remain with the company and contribute to its future performance.

Industry Context

Executive compensation, particularly through equity grants like RSUs, is a standard practice across industries to align executive incentives with shareholder interests and promote long-term retention. The specific value and vesting schedule would be benchmarked against peer companies in the biotechnology or pharmaceutical sector.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for executive compensation is a common practice in the biotechnology and pharmaceutical industry, similar to companies like Pfizer or Moderna, to incentivize long-term performance and retention.
• A four-year vesting schedule (1/4 immediately, then annually) is a standard industry practice, comparable to equity compensation plans at companies such as Amgen or Gilead Sciences, ensuring executive commitment over a sustained period.
• The grant size of 93,010 units for a Chief Operating Officer would typically be evaluated against the company's market capitalization, revenue, and the executive's specific responsibilities, as well as compensation benchmarks for similar roles at peer companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with long-term company performance and retention of key talent.
• Employees: May signal stability in executive leadership.

Next Steps

• Continued vesting of the remaining 3/4 of the restricted stock units on the first, second, and third anniversaries of the grant date (January 23, 2027, January 23, 2028, and January 23, 2029), subject to continued employment.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU grant and tax-related disposition) for the Chief Operating Officer. While it aligns executive incentives with long-term shareholder value, it does not present new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as it maintains the current stance based on existing company fundamentals.

Keywords

CorMedix Inc., CRMD, Form 4, Restricted Stock Units, RSU, Executive Compensation, Insider Trading, Elizabeth Hurlburt, Stock Grant, Vesting Schedule